Peanut Allergy - Competitive Landscape, Market Insights, Epidemiology and Market Forecast 2025

  • ID: 4436379
  • Drug Pipelines
  • 163 Pages
  • DelveInsight
1 of 4
The Reported Prevalent Cases of Peanut Allergy in 2015 Were 6,719,025 in 7MM and Estimated to Increase in Coming Years

FEATURED COMPANIES

  • Aimmune
  • Allergy Therapeutics
  • AnaptysBio
  • ASIT biotech
  • BioLingus
  • DBV Technologies
  • MORE

Peanut Allergy - Competitive Landscape, Market Insights, Epidemiology and Market Forecast 2025 provides comprehensive insights on the therapeutics development and the global market trends for the seven major markets i.e. United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The report covers the therapeutics market revenue, treatment practice and Peanut Allergy forecasted market share from 2017 to 2025, along with the global epidemiological forecast for this indication.

The reported prevalent cases of Peanut Allergy in 2015 were 6,719,025 in 7MM and estimated to increase in coming years. In certain European countries prevalence will decrease owing to the overall decrease in population. Currently there is no effective therapeutics or prophylactic products are available in market. The historical and current market size for this allergy comprises of Epinephrine and Anti-histamines. The first entry of Peanut Allergy treatment is expected in 2019 in US.

The report also includes therapeutic competitive landscape including 15+ pipeline products in this space. It further provides comparative pipeline analysis at various stages covering Phase III, Phase II, Phase I, Pre-clinical and Discovery. Active pipeline therapeutics assessment by stage, therapy type, route of administration and molecule type is also provided. Additionally, it also features the dormant and discontinued pipeline products. Leading companies in this space are Aimmune, DBV Technologies and AnaptysBio.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

Secondary sources information and data has been collected from various printable and nonprintable sources like search engines, news websites, government websites, trade journals, white papers, magazines, trade associations, books, industry portals, industry associations and available databases.

Scope:

  • Overview of peanut allergy products
  • Pipeline scenario for peanut allergy development from different companies and research institutes
  • Competitive landscape of products
  • Pipeline analysis across different phases, emerging trends and comparative analysis of pipeline products with detailed clinical profiles including: mechanism of action, route of administration and molecule type along with product development activities
  • Coverage of licensors, collaborators and development partners, deal terms and deal values
  • Insights regarding market forecasts in peanut allergy domain
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Aimmune
  • Allergy Therapeutics
  • AnaptysBio
  • ASIT biotech
  • BioLingus
  • DBV Technologies
  • MORE
  1. Peanut Allergy - Overview
  2. Peanut Allergens
  3. Symptoms
  4. Clinical Symptoms
  5. Risk Factors
  6. Causes
  7. Test and Diagnosis
  8. Peanut Allergy Management and Treatment
  9. Being prepared for a reaction
  10. Prevalence
  11. Scientific Research
  12. Experimental Approaches
  13. Sensitization
  14. To Do/Not to Do
  15. Epidemiology Overview - 7MM, 2015-2025
  16. Prevalence of Peanut Allergy in 7MM
  17. Key Findings
  18. Epidemiology of Peanut Allergy in 7 MM
  19. Assumptions and Rationale
  20. Prevalent Population of Peanut Allergy in 7MM
  21. United States
  22. Assumptions and Rationale
  23. Prevalent Population of Peanut Allergy
  24. Age Specific Prevalent Population
  25. Gender Specific Prevalent Population
  26. Severity Specific Prevalent Population
  27. Serious Conditions (Fatal & Emergency Cases)
  28. Europe
  29. Assumptions and Rationale
  30. United Kingdom
  31. Assumptions and Rationale
  32. Prevalent Population of Peanut Allergy
  33. Age Specific Prevalence
  34. Gender Specific Prevalence
  35. Severity Specific Prevalence
  36. France
  37. Assumptions and Rationale
  38. Prevalent Population of Peanut Allergy
  39. Age Specific Prevalence
  40. Gender Specific Prevalence
  41. Severity Specific Prevalence
  42. Germany
  43. Assumptions and Rationale
  44. Prevalent Population of Peanut Allergy
  45. Age Specific Prevalence
  46. Gender Specific Prevalence
  47. Severity Specific Prevalence
  48. Italy
  49. Assumptions and Rationale
  50. Prevalent Population of Peanut Allergy
  51. Age Specific Prevalence
  52. Gender Specific Prevalence
  53. Severity Specific Prevalence of Peanut Allergy
  54. Spain
  55. Assumptions and Rationale
  56. Prevalent Population of Peanut Allergy
  57. Age Specific Prevalence
  58. Gender Specific Prevalence
  59. Severity Specific Prevalence
  60. Japan
  61. Assumptions and Rationale
  62. Prevalent Population of Peanut Allergy
  63. Age Specific Prevalence
  64. Gender Specific Prevalence
  65. Severity Specific Prevalence
  66. Pipeline Therapeutics
  67. Competitive Landscape
  68. Comparative Analysis
  69. Product Type
  70. Late Stage Products (Phase III)
  71. Comparative Analysis
  72. AR101: Aimmune Therapeutics
  73. Product Description
  74. Research and Development
  75. Product Development Activities
  76. More drugs in detailed report
  77. Mid Stage Products (Phase II)
  78. Comparative Analysis
  79. ANB020: AnaptysBio
  80. Product Description
  81. Research and Development
  82. Product Development Activities
  83. More drugs in detailed report
  84. Early Stage Products (Phase I)
  85. Comparative Analysis
  86. SAR-439794: Sanofi
  87. Product Description
  88. Research and Development
  89. Product Development Activities
  90. More drugs in detailed report
  91. Pre-clinical and Discovery Products
  92. Comparative Analysis
  93. SVP-CPE + SVP-Resiquimod: Selecta Biosciences
  94. Product Description
  95. Research and Development
  96. Product Development Activities
  97. More drugs in detailed report
  98. Therapeutic Assessment
  99. Assessment by Route of Administration
  100. Assessment by Stage and Route of Administration
  101. Assessment by Molecule Type
  102. Assessment by Stage and Molecule Type
  103. Dormant and Discontinued Products
  104. Comparative Analysis
  105. Market Assessment: 7MM
  106. 7MM Market Size
  107. United States Market Size
  108. EU5 Market Size
  109. United Kingdom Market Size
  110. France Market Size
  111. Germany Market Size
  112. Italy Market Size
  113. Spain Market Size
  114. Japan Market Size
  115. Appendix

List of Tables
Table 1: 7MM, Historical & Forecasted Peanut Allergy Cases, 2015-2025
Table 2: United States, Historical & Forecasted Peanut Allergy Cases, 2015-2025
Table 3: United States, Age Specific Prevalence of Peanut Allergy Cases, 2015-2025
Table 4: United States, Gender Specific Prevalence of Peanut Allergy Cases in Children, 2015-2025
Table 5: United States, Gender Specific Prevalence of Peanut Allergy Cases in Adults, 2015-2025
Table 6: United States, Severity Specific Prevalence of Peanut Allergy Cases, 2015-2025
Table 7: United States, Serious Conditions of Peanut Allergy, 2015-2025
Table 8: United Kingdom, Historical & Forecasted Peanut Allergy Cases, 2015-2025
Table 9: United Kingdom, Age Specific Prevalence of Peanut Allergy Cases, 2015-2025
Table 10: United Kingdom, Gender Specific Prevalence of Peanut Allergy Cases in Children, 2015-2025
Table 11: United Kingdom, Gender Specific Prevalence of Peanut Allergy Cases in Adults, 2015-2025
Table 12: United Kingdom, Severity Specific Prevalence of Peanut Allergy Cases, 2015-2025
Table 13: France, Historical & Forecasted Peanut Allergy Cases, 2015-2025
Table 14: France, Age Specific Prevalence of Peanut Allergy Cases, 2015-2025
Table 15: France, Gender Specific Prevalence of Peanut Allergy Cases in Children, 2015-2025
Table 16: France, Gender Specific Prevalence of Peanut Allergy Cases in Adults, 2015-2025
Table 17: France, Severity Specific Prevalence of Peanut Allergy Cases, 2015-2025
Table 18: Germany, Historical & Forecasted Peanut Allergy Cases, 2015-2025
Table 19: Germany, Age Specific Prevalence of Peanut Allergy Cases, 2015-2025
Table 20: Germany, Gender Specific Prevalence of Peanut Allergy Cases in Children, 2015-2025
Table 21: Germany, Gender Specific Prevalence of Peanut Allergy Cases in Adults, 2015-2025
Table 22: Germany, Severity Specific Prevalence of Peanut Allergy Cases, 2015-2025
Table 23: Italy, Historical & Projected Prevalence of Peanut Allergy Cases, 2015-2025
Table 24: Italy, Age Specific Prevalence of Peanut Allergy Cases, 2015-2025
Table 25: Italy, Gender Specific Prevalence of Peanut Allergy in Children, 2015-2025
Table 26: Italy, Gender Specific Prevalence of Peanut Allergy Cases in Adults, 2015-2025
Table 27: Italy, Severity Specific Prevalence of Peanut Allergy Cases, 2015-2025
Table 28: Spain, Historical & Forecasted Peanut Allergy Cases, 2015-2025
Table 29: Spain, Age Specific Prevalence of Peanut Allergy Cases, 2015-2025
Table 30: Spain, Gender Specific Prevalence of Peanut Allergy Cases in Children, 2015-2025
Table 31: Spain, Gender Specific Prevalence of Peanut Allergy Cases in Adults, 2015-2025
Table 32: Spain, Severity Specific Prevalence of Peanut Allergy Cases, 2015-2025
Table 33: Japan, Historical & Forecasted Peanut Allergy Cases, 2015-2025
Table 34: Japan, Age Specific Prevalence of Peanut Allergy Cases, 2015-2025
Table 35: Japan, Gender Specific Prevalence of Peanut Allergy Cases in Children, 2015-2025
Table 36: Japan, Gender Specific Prevalence of Peanut Allergy Cases in Adults, 2015-2025
Table 37: Japan, Severity Specific Prevalence of Peanut Allergy Cases, 2015-2025
Table 38: Total Products for Peanut Allergy
Table 39: Peanut Allergy Product Type
Table 40: Late Stage Products (Phase III)
Table 43: Mid Stage Products (Phase II)
Table 45: Early Stage Products (Phase I)
Table 46: Pre-clinical and Discovery Stage Products
Table 47: Assessment by Route of Administration
Table 48: Assessment by Stage and Route of Administration
Table 49: Assessment by Molecule Type
Table 50: Assessment by Stage and Molecule Type
Table 51: Dormant Products
Table 52: Discontinued Products

List of Figures
Figure 1: 7MM, Historical & Forecasted Peanut Allergy, 2015-2025
Figure 2: United States, Historical & Forecasted Peanut Allergy Cases, 2015-2025
Figure 3: United States, Age Specific Prevalence of Peanut Allergy Cases, 2015-2025
Figure 4: United States, Gender Specific Prevalence of Peanut Allergy Cases in Children, 2015-2025
Figure 5: United States, Gender Specific Prevalence of Peanut Allergy Cases in Adults, 2015-2025
Figure 6: United States, Severity Specific Prevalence of Peanut Allergy Cases, 2015-2025
Figure 7: United Kingdom, Historical & Forecasted Peanut Allergy Cases, 2015-2025
Figure 8: United Kingdom, Age Specific Prevalence of Peanut Allergy Cases, 2015-2025
Figure 9: United Kingdom, Gender Specific Prevalence of Peanut Allergy Cases in Children, 2015-2025
Figure 10: United Kingdom, Gender Specific Prevalence of Peanut Allergy Cases in Adults, 2015-2025
Figure 11: United Kingdom, Severity Specific Prevalence of Peanut Allergy Cases, 2015-2025
Figure 12: France, Historical & Forecasted Peanut Allergy Cases, 2015-2025
Figure 13: France, Age Specific Prevalence of Peanut Allergy Cases, 2015-2025
Figure 14: France, Gender Specific Prevalence of Peanut Allergy Cases in Children, 2015-2025
Figure 15: France, Gender Specific Prevalence of Peanut Allergy Cases in Adults, 2015-2025
Figure 16: France, Severity Specific Prevalence of Peanut Allergy Cases, 2015-2025
Figure 17: Germany, Historical & Forecasted Peanut Allergy Cases, 2015-2025
Figure 18: Germany, Age Specific Prevalence of Peanut Allergy Cases, 2015-2025
Figure 19: Germany, Gender Specific Prevalence of Peanut Allergy Cases in Children, 2015-2025
Figure 20: Germany, Gender Specific Prevalence of Peanut Allergy Cases in Adults, 2015-2025
Figure 21: Germany, Severity Specific Prevalence of Peanut Allergy Cases, 2015-2025
Figure 22: Italy, Historical & Projected Prevalence of Peanut Allergy Cases, 2015-2025
Figure 23: Italy, Age Specific Prevalence of Peanut Allergy Cases, 2015-2025
Figure 24: Italy, Gender Specific Prevalence of Peanut Allergy in Children, 2015-2025
Figure 25: Italy, Gender Specific Prevalence of Peanut Allergy Cases in Adults, 2015-2025
Figure 26: Italy, Severity Specific Prevalence of Peanut Allergy Cases, 2015-2025
Figure 27: Spain, Historical & Forecasted Peanut Allergy Cases, 2015-2025
Figure 28: Spain, Age Specific Prevalence of Peanut Allergy Cases, 2015-2025
Figure 29: Spain, Gender Specific Prevalence of Peanut Allergy Cases in Children, 2015-2025
Figure 30: Spain, Gender Specific Prevalence of Peanut Allergy Cases in Adults, 2015-2025
Figure 31: Spain, Severity Specific Prevalence of Peanut Allergy Cases, 2015-2025
Figure 32: Japan, Historical & Forecasted Peanut Allergy Cases, 2015-2025
Figure 33: Japan, Age Specific Prevalence of Peanut Allergy, 2015-2025
Figure 34: Japan, Gender Specific Prevalence of Peanut Allergy Cases in Children, 2015-2025
Figure 35: Japan, Gender Specific Prevalence of Peanut Allergy Cases in Adults, 2015-2025
Figure 36: Japan, Severity Specific Prevalence of Peanut Allergy Cases, 2015-2025
Figure 37: Total Products for Peanut Allergy
Figure 38: Peanut Allergy Product Type
Figure 39: Late Stage Products (Phase III)
Figure 40: Mid Stage Products (Phase II)
Figure 41: Early Stage Products (Phase I)
Figure 42: Pre-clinical and Discovery Stage Products
Figure 43: Assessment by Route of Administration
Figure 44: Assessment by Stage and Route of Administration
Figure 45: Assessment by Molecule Type
Figure 46: Assessment by Stage and Molecule Type
Figure 47: Dormant and Discontinued Products
Figure 48: 7MM Overall Market Size
Figure 49: United States Market Size for Peanut Allergy
Figure 50: EU5 Market Size
Figure 51: United Kingdom Market Size
Figure 52: France Market Size
Figure 53: Germany Market Size
Figure 54: Italy Market Size
Figure 55: Spain Market Size
Figure 56: Japan Market Size

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Aimmune
  • Allergy Therapeutics
  • AnaptysBio
  • ASIT biotech
  • BioLingus
  • DBV Technologies
  • Genentech
  • Laboratorios LETI
  • Prota Therapeutics
  • Selecta Biosciences
  • Virtici
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll